CAMERON CAMPBELL: Open Payments
NPI 1497149348 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$341 in 16 payments from 9 companies in 2025. Trend: 2023 $409 · 2024 $377 · 2025 $341
Food & beverage: $341
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 6 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| ABBVIE INC. | 2 | $41 |
| GENZYME CORPORATION | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| GlaxoSmithKline, LLC. | 1 | $29 |
| Gilead Sciences, Inc. | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
| TMS NeuroHealth Centers Inc. | 1 | $16 |
Products named: NURTEC ODT, CAPLYTA, SARCLISA, HETLIOZ, TRELEGY ELLIPTA, QULIPTA, UBRELVY, ELIQUIS.
Industry payments across MD — which companies pay providers there.
